Zai Lab (ZLAB) announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, an IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis. ZL-1503, which was identified and advanced internally by Zai Lab’s discovery team, targets both IL-13 and IL-31 pathways with an extended serum half-life. The dual targeting potentially provides faster onset of action and superior efficacy.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Zai Lab announces updates to China’s National Reimbursement Drug List
- Zai Lab Ltd’s Earnings Call: Mixed Outlook Amid Growth and Challenges
- Zai Lab Reports Strong Q3 2025 Growth and Pipeline Progress
- Zai Lab reports Q3 EPS (3c), consensus (29c)
- Zai Lab sees FY25 revenue at least $460M, consensus $556.41M